Havrix is a sterile suspension of inactivated virus strain HM175 which is propagated in MRC-5 human diploid cells. After removal of the cell culture medium, the cells are lysed to form a suspension. This suspension is purified through ultrafiltration and gel permeation chromatography procedures. Treatment of this lysate with formalin ensures viral inactivation.
Havrix is a vaccine indicated for active immunization against disease caused by hepatitis A virus (HAV).
Havrix is administered by intramuscular injection.
- Children and adolescents: A single 0.5-mL dose and a 0.5-mL booster dose administered between 6 to 12 months later.
- Adults: A single 1-mL dose and a 1-mL booster dose administered between 6 to 12 months later.
- Primary immunization should be administered at least 2 weeks prior to expected exposure to HAV.